Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
2(18%)
Results Posted
50%(3 trials)
Terminated
2(18%)

Phase Distribution

Ph early_phase_1
1
9%
Ph phase_2
7
64%
Ph phase_3
1
9%
Ph phase_1
2
18%

Phase Distribution

3

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Early Phase 1First-in-human
1(9.1%)
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
7(63.6%)
Phase 3Large-scale testing
1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(6)
Terminated(3)

Detailed Status

Completed6
Active, not recruiting2
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (9.1%)
Phase 12 (18.2%)
Phase 27 (63.6%)
Phase 31 (9.1%)

Trials by Status

withdrawn19%
completed655%
active_not_recruiting218%
terminated218%

Recent Activity

2 active trials
Showing 5 of 11
completedphase_2

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

NCT02314481
active_not_recruitingphase_2

MPDL3280A With Chemoradiation for Lung Cancer

NCT02525757
completedphase_2

A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

NCT03519295
completedphase_2

Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder

NCT02662309
active_not_recruitingphase_2

MPDL3280A-treatment-IST-UMCG

NCT02478099
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT02314481Phase 2

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Completed
NCT02525757Phase 2

MPDL3280A With Chemoradiation for Lung Cancer

Active Not Recruiting
NCT03519295Phase 2

A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Completed
NCT02662309Phase 2

Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder

Completed
NCT02478099Phase 2

MPDL3280A-treatment-IST-UMCG

Active Not Recruiting
NCT02620280Phase 3

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

Completed
NCT02716038Phase 2

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

Completed
NCT02630186Phase 1

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Terminated
NCT02463994Early Phase 1

A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

Completed
NCT02748889Phase 1

Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer

Terminated
NCT02495636Phase 2

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Withdrawn

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11